Company news

PDS Biotechnology Corporation news in 2025

PDS Biotechnology Corporation's news releases, calls and decks from 2025, newest first.

View company

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

December 9, 2025

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

December 2, 2025

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

November 13, 2025

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

November 11, 2025

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

November 10, 2025

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

November 6, 2025

New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 30, 2025

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

October 29, 2025

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

September 18, 2025

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

August 25, 2025

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

August 13, 2025

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

August 6, 2025

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

July 10, 2025

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

June 9, 2025

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 2, 2025

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 20, 2025

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 14, 2025

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 8, 2025

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

May 7, 2025

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2025

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

April 16, 2025

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

April 8, 2025

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

March 27, 2025

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

March 25, 2025

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

March 18, 2025

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

March 13, 2025

PDS Biotech Leadership to Participate in March Conferences

March 11, 2025

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

March 7, 2025

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

February 27, 2025

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

February 26, 2025

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

February 24, 2025

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

February 20, 2025

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

February 4, 2025

Calls in 2025

Decks in 2025